About Us

Founded in 2019 by scientific pioneers who started the fields of Cardiac Gene Therapy over three decades ago at the Massachusetts General Hospital, Sardocor is a fully owned subsidiary of the Medera Group.

Sardocor is dedicated to the clinical development of novel therapies for patients with incurable diseases. With three ongoing gene therapy clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF) and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), Sardocor is currently second to none in terms of the number of FDA Investigational New Drug (IND) approvals and the clinical stage maturity.